OSR2

OSR2 is a zinc-finger transcription factor that patterns developing tissues by restricting morphogenetic signaling domains and, in immune cells, epigenetically represses cytotoxic gene programs to drive T cell exhaustion. In craniofacial and tooth development, OSR2 acts downstream of Pax9 and directly binds promoters of target genes (Sema3a, Sema3d, Bmp4) to repress their transcription, thereby establishing lingual-buccal gradients that constrain the odontogenic field and prevent supernumerary tooth formation through antagonism of the BMP4-Msx1 and canonical Wnt signaling pathways (PMID:19251632, PMID:28731788, PMID:27713059). OSR2 and its paralog OSR1 function redundantly in synovial joint maintenance—where they sustain Gdf5 and Wnt4/9b expression—and in lung specification, where they act upstream of Wnt2b (PMID:21262216, PMID:22791896); heterozygous OSR2 loss-of-function variants cause radioulnar synostosis in humans (PMID:41424369). In terminally exhausted CD8+ T cells within tumors, OSR2 is induced by Piezo1/calcium/CREB mechanosensory signaling and recruits the histone deacetylase HDAC3 to epigenetically silence cytotoxic effector genes, and its depletion reinvigorates anti-tumor T cell and CAR-T cell responses (PMID:38744281).

1. 2001 Medium

   Molecular cloning established OSR2 as a zinc-finger protein with two alternatively spliced isoforms, closely related to OSR1, and expressed at sites of epithelial–mesenchymal interaction during tooth and kidney development, framing it as a developmental transcription factor.

   Evidence Gene cloning, sequence analysis, whole-mount in situ hybridization, and RT-PCR in mouse embryos

   PMID:11520675

   Open questions at the time

   • Single-lab characterization
   • No functional data on transcriptional activity
   • Protein localization beyond mRNA expression patterns not determined
2. 2004 High

   Osr2 null mice revealed that OSR2 is required for palatal shelf growth by promoting mesenchyme proliferation in a region-specific manner, establishing its first loss-of-function phenotype and identifying cleft palate as the primary developmental consequence.

   Evidence Targeted null mutation in mice with histological analysis, cell proliferation assays, and in situ hybridization

   PMID:15175245

   Open questions at the time

   • Transcriptional targets mediating the proliferation defect unknown
   • Mechanism of medial-lateral regionalization of OSR2 function unclear
3. 2009 High

   Genetic epistasis using Osr2/Msx1 double mutants demonstrated that OSR2 restricts the odontogenic field by repressing BMP4 expression along a lingual-to-buccal gradient, and that supernumerary tooth formation in Osr2 knockouts depends on Msx1, placing OSR2 as an antagonist of the BMP4-Msx1 pathway. Concurrently, knockin experiments showed OSR1 and OSR2 are biochemically equivalent, with distinct in vivo roles arising from cis-regulatory divergence.

   Evidence Osr2 KO and Osr2/Msx1 double KO mice with molecular marker analysis; Osr1-into-Osr2 knockin rescue mice

   PMID:19251632 PMID:19389375

   Open questions at the time

   • Direct DNA-binding targets of OSR2 not yet identified
   • Whether OSR2 directly represses Bmp4 transcription or acts indirectly not resolved
4. 2011 High

   OSR2 was shown to physically interact with Msx1 and weakly with Pax9 by co-immunoprecipitation, and genetic epistasis placed OSR2 downstream of Pax9 in tooth patterning; simultaneously, redundant roles of OSR1/OSR2 in synovial joint formation were demonstrated, with double knockouts showing joint fusion and loss of Gdf5/Wnt4/Wnt9b expression.

   Evidence Co-IP in co-transfected cells, Pax9-Osr2 knockin rescue mice, conditional Osr1/Osr2 double KO in limb mesenchyme

   PMID:21262216 PMID:21420399

   Open questions at the time

   • Whether OSR2-Msx1 interaction occurs on chromatin not tested
   • Mechanism by which OSR2 maintains joint-specific gene expression unknown
   • Co-IP performed in overexpression system, endogenous interaction not confirmed
5. 2012 High

   Xenopus studies established that OSR1/OSR2 act as transcriptional repressors of Bmp4 in lateral plate mesoderm and are required upstream of Wnt2b for lung/trachea/esophagus specification, broadening OSR2 function beyond craniofacial tissues to foregut organogenesis.

   Evidence Morpholino knockdown in Xenopus with epistasis experiments and gain-of-function assays

   PMID:22791896

   Open questions at the time

   • Whether OSR2 directly represses Bmp4 or acts through intermediaries in Xenopus not determined
   • Mammalian lung phenotype from Osr2 loss not characterized
6. 2013 High

   Direct regulation of Osr2 by Pax9 in palatal mesenchyme was confirmed when an Osr2 knockin into the Pax9 locus rescued posterior palate morphogenesis in Pax9 mutants, solidifying the Pax9→OSR2→Bmp4/Fgf10/Shh regulatory hierarchy.

   Evidence Pax9 conditional KO, Pax9(Osr2KI) knockin rescue, in situ hybridization

   PMID:24173808

   Open questions at the time

   • Whether Pax9 directly binds Osr2 cis-regulatory elements not tested by ChIP
7. 2016 High

   RNA-seq and pharmacological rescue experiments revealed that OSR2 antagonizes canonical Wnt signaling in tooth mesenchyme by promoting expression of secreted Wnt antagonists Dkk2 and Sfrp2, and that Wnt pathway activation can bypass Msx1 loss, integrating OSR2 into the Wnt-BMP crosstalk network.

   Evidence RNA-seq of mutant tooth mesenchyme, in utero LiCl and DKK inhibitor treatment, genetic compound mutants

   PMID:27713059

   Open questions at the time

   • Whether OSR2 directly activates Dkk2/Sfrp2 transcription or acts indirectly not resolved
8. 2017 High

   ChIP-PCR demonstrated that endogenous OSR2 directly binds promoters of Sema3a and Sema3d in palatal mesenchyme and represses their transcription, providing the first direct chromatin occupancy data and identifying semaphorin signaling as a downstream effector of OSR2 in palate development.

   Evidence ChIP-PCR on embryonic palatal mesenchyme, co-transfection reporter assay, RNA-seq

   PMID:28731788

   Open questions at the time

   • Genome-wide binding profile (ChIP-seq) not performed
   • Whether semaphorin repression is the primary mechanism preventing cleft palate not tested
9. 2022 High

   Outside developmental contexts, MAX was shown to directly bind the OSR2 promoter and activate OSR2 transcription in human endometrial stromal cells, and OSR2 knockdown impaired decidualization, revealing a role in endometrial differentiation.

   Evidence ChIP-seq, CUT&RUN-seq, dual-luciferase reporter, siRNA knockdown and overexpression rescue in HESCs

   PMID:35146559

   Open questions at the time

   • OSR2 transcriptional targets in decidualization not identified
   • In vivo endometrial phenotype not examined
10. 2024 High

    A mechanistically distinct role for OSR2 in immunity was established: in terminally exhausted CD8+ T cells, Piezo1-mediated biomechanical signaling activates OSR2 via calcium/CREB, and OSR2 recruits HDAC3 to suppress cytotoxic gene programs epigenetically, with Osr2 depletion reinvigorating anti-tumor T cell responses.

    Evidence Conditional KO and overexpression in CD8+ T cells, Co-IP of OSR2-HDAC3, chromatin accessibility assays, solid tumor mouse models, pharmacological Piezo1 manipulation

    PMID:38744281

    Open questions at the time

    • Genome-wide OSR2-HDAC3 co-occupancy sites not mapped
    • Whether OSR2 plays roles in other immune cell types unknown
    • Therapeutic window of OSR2 targeting in cancer immunotherapy not defined
11. 2025 Medium

    Heterozygous loss-of-function OSR2 variants were identified as a cause of radioulnar synostosis in humans, with missense mutations impairing nuclear localization, directly translating the mouse joint-fusion phenotype to a human Mendelian skeletal disorder.

    Evidence Exome sequencing, chromosomal microarray, immunofluorescence for nuclear localization, Western blot

    PMID:41424369

    Open questions at the time

    • Single study; independent replication in additional cohorts needed
    • Transcriptional consequences of impaired nuclear entry not characterized
    • Whether haploinsufficiency versus dominant-negative mechanism applies not fully resolved

• Key unresolved questions include the genome-wide direct target repertoire of OSR2 (no ChIP-seq exists), the structural basis for its dual activator/repressor function, how tissue-specific cofactor recruitment (e.g., HDAC3 in T cells versus unknown partners in mesenchyme) is determined, and whether OSR2's immunological role extends beyond CD8+ T cell exhaustion.
• No genome-wide ChIP-seq binding map
• No crystal or cryo-EM structure
• Cofactor selectivity mechanism unknown